The Journal of Antibiotics Медицина (общая)

Tsukubacyclinone, a novel angucyclinone compound with anti-inflammatory activity in synovial cell line SW982, produced by Streptomyces sp. K21-0141

Iizuka, Fumito, Uchida, Kentaro, Kikuchi, Yuta, Awano, Yuta, Nagayoshi, Miho, Ikeuchi, Saki, Takeda, Kugo, Ohashi, Yoshihisa, Inoue, Gen, Hirose, Tomoyasu, Inahashi, Yuki
Springer Nature · 2026-09-01 · DOI 10.1038/s41429-026-00943-x

Аннотация

Streptomyces species are prolific producers of structurally diverse secondary metabolites with a broad spectrum of biological activities. In this study, we isolated a novel angucyclinone compound, tsukubacyclinone ( 1 ), from the culture broth of Streptomyces sp. K21-0141. Tsukubacyclinone ( 1 ) exhibited potent anti-inflammatory effects in vitro. RNA sequencing of TNF-α–stimulated synovial cell line, SW982 revealed that tsukubacyclinone ( 1 ) downregulated pro-inflammatory genes, including IL1B and IL6 , which was further validated by qPCR, without increasing LDH activity. KEGG pathway analysis indicated modulation of TNF, NF-κB, cytokine–cytokine receptor interaction, and JAK–STAT signaling. ELISA further confirmed a dose-dependent suppression of IL-1β and IL-6 protein. These findings suggest that tsukubacyclinone ( 1 ), as a novel angucyclinone-type compound, may target upstream cytokine signaling pathways to attenuate synovial inflammation, highlighting its potential as a disease-modifying agent for osteoarthritis and other chronic joint diseases. Future studies are warranted to investigate its in vivo pharmacological effects and molecular targets.

Читать у издателя →